ELI LILLY & Co is 922.1x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($1.072 T vs $1.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | XERS | LLY |
|---|---|---|
| Market cap | $1.16 B | $1.072 T |
| US-listed rank | #2530 | #10 |
| Revenue (latest FY) | $291.85M | $65.18B |
| Net income (latest FY) | $554.00K | $20.64B |
| Net margin | 0.2% | 31.7% |
| P/E (trailing FY) | 2098.8 | 51.9 |
| SEC filings | 290 | 989 |
ELI LILLY & Co is 922.1x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($1.072 T vs $1.16 B).
In their latest fiscal years, Xeris Biopharma Holdings, Inc. reported $291.85M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Xeris Biopharma Holdings, Inc. and ELI LILLY & Co, or browse the full rankings.